Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834093 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00834093 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT00834093, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the participant's body. This is phase II study with the aim of establishing a baseline of efficacy.
Interventions
- BIOLOGICAL Epstein-Barr Virus Specific Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-04 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834093
The ClinicalTrials.gov registry entry for NCT00834093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Epstein-Barr Virus Specific Immunotherapy is the first listed.
NCT00834093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834093 about?
NCT00834093 is a clinical study titled "A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma". The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the participant's body. This is phase I...
What is the current status of trial NCT00834093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-04. Estimated completion is 2017-02.
What interventions are being tested in trial NCT00834093?
The interventions under investigation include: Epstein-Barr Virus Specific Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00834093?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.